Bayer AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bill Anderson
- Full Time Employees
- 88,078
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Kaiser-Wilhelm-Allee 1 Leverkusen NW Germany 51368
- IPO Date
- Nov 18, 1996
- Website
- bayer.com
- Similar Companies
- Business
- Bayer AG is a global life science company headquartered in Leverkusen, Germany, primarily engaged in the healthcare and agriculture sectors. The company operates through three main segments: Pharmaceuticals, Consumer Health, and Crop Science. Its Pharmaceuticals segment develops, manufactures, and markets prescription medicines focusing on cardiology, oncology, hematology, ophthalmology, women's health, and specialized therapies including cell and gene therapies. The Consumer Health division offers over-the-counter products spanning nutritional supplements, allergy relief, cough and cold remedies, dermatology products, pain management, cardiovascular risk prevention, and digestive health. Bayer’s Crop Science unit provides products and services in crop protection, seeds and traits, digital farming, fruits and vegetables, and environmental science solutions aimed at sustainable agriculture. Bayer maintains a global footprint with operations across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. Founded in 1863, Bayer continues to be a leader in pharmaceutical and agricultural innovation. In recent major developments during 2024 and 2025, Bayer has continued its corporate restructuring under the Dynamic Shared Ownership operating model introduced in early 2024, aiming to increase agility and operational efficiency. This has involved workforce reductions of approximately 12,000 jobs worldwide, focusing on management and administrative layers, with expected annual cost savings of up to 2 billion euros by 2026. Bayer has advanced a differentiated pharmaceutical pipeline targeting oncology, cardiovascular diseases, neurology, rare diseases, and immunology, with anticipated product launches including treatments for heart failure and hormone-free solutions for menopausal symptoms by the end of 2025. It also pursues growth in cell and gene therapy and targeted radiopharmaceuticals. On the Crop Science front, Bayer is rolling out innovations such as the Preceon Smart Corn System and new herbicides while focusing on digital farming and environmental sustainability. Despite pressure from investors to divest or break up its business units, Bayer has postponed any structural separation, instead emphasizing portfolio management and strategic alliances. The company also navigates significant legal provisions related to litigation over its Roundup weedkiller product. Overall, Bayer maintains a strong commitment to research and development to support its leadership in life sciences globally.
Company News
Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript
Bayer Crop Science Targets €3B Cash Flow by 2029 With Seeds-Led Growth
Bayer says Crop Science unit makes progress on product launches
Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
Bayer Aktiengesellschaft (BAYRY) Q2 2026 Earnings Call Transcript
Bayer: De-Risking Is Real, But The Pharma Cliff Keeps Me On Hold
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
Bayer Aktiengesellschaft Q2 Earnings Call Highlights
Bayer Swings to Net Profit on Smaller Litigation Charges
Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
Bayer: Debt Remains A Problem, Value Remains Compelling
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
Bayer gets €3 billion in Apollo deal for contraceptives unit
Bayer seeks US duties on Chinese-made glyphosate, angering farmers
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
BAYRY Stock Surges 17% After Supreme Court Roundup Ruling